175 results about "DNA methylation" patented technology

The application provides a novel DNA methylation marker TAGMe-3 for tumor identification and use thereof. The TAGMe-3 gene sequence region has significant methylation difference between cancer tissues and paracancer tissues. As long as abnormal high methylation state of the TAGMe-3 gene sequence region is detected, the subject is determined to belong to a tumor high-risk population. Moreover, the significant difference of the TAGMe-3 presented between tumor tissues and non-tumor tissues exists in different types of tumors (Pan-cancer) in a wide range.

The present invention discloses an in vitro method for obtaining DNA methylation biomarkers as exquisite DNA methylation positions in the human genome (i.e., CGIDs) that predict cervical cancer especially at as yet inaccessible early stages by examining progression of “categorical” DNA methylation alterations in three stages of premalignant lesions (cervical intraepithelial neoplasia (CIN)), progressing from CIN1 to CIN3. The present invention discloses combinations of CGIDs for detecting with high specificity and sensitivity cervical cancer by measuring their DNA methylation status and deriving a “methylation score”, which is useful as a biomarker for cervical cancer. Also disclosed are kits for predicting cervical cancer using such CGIDs using multiplexed next generation sequencing methylation assays, pyrosequencing assays and methylation specific PCR. The DNA methylation markers (CGIDs) described in the present invention are useful for cervical screening and early detection of cervical cancer by any person skilled in the art to detect cervical cancer.

This invention discloses a method for constructing a gene methylation diagnostic model for differentiated thyroid cancer (PTC). The method includes the following steps: S1, obtaining a test sample; S2, extracting and storing DNA from the test sample; S3, performing methylation analysis; S4, establishing a diagnostic model based on DNA methylation, where the model shows that patients with cg03596178, cg06033721, cg06688989, cg07209244, cg07485775, cg14484681, cg19979108, and cg20943461 are more likely to experience disease progression and are considered risk factors; S5, cross-validating and evaluating the performance to obtain the gene methylation diagnostic model. This model, by detecting and statistically analyzing specific methylation sites, can differentiate patients with recurrent or metastatic characteristics in differentiated thyroid cancer. The relevant model can assist in the clinical diagnosis and follow-up of thyroid patients.

The present disclosure generally relates to methods and compositions for interrogating and / or analyzing DNA methylation in a biological sample. In some aspects, the present disclosure relates to methods for determining the methylation status of a region of interest of genomic DNA. In some aspects, the methylation status is analyzed by interrogating converted DNA in which the sequence of the converted DNA is indicative of the methylation state of the DNA. In some aspects, the methods comprise generating a collective signal that is based on the methylation states of a plurality of sequences or residues in the DNA, and that is representative of the methylation status of the region of interest as a whole.

The invention discloses a gene level DNA methylation, transcriptome and proteome conjoint analysis method based on a snkemake framework, which comprises the following steps: preprocessing original data of DNA methylation and / or transcriptome and / or proteome, analyzing gene methylation, analyzing transcriptome and / or proteome, and analyzing the transcriptome and proteome. Based on gene methylation analysis data, the preprocessed transcriptome data and the preprocessed proteome data, correlation analysis and / or difference intersection analysis and / or enrichment pathway conjoint analysis are / is carried out, finally analysis results are sorted, and a visual report is generated. The method has comprehensive results, and relates to quantification, difference analysis and pathway enrichment analysis of gene methylation, and correlation analysis, difference intersection analysis and enrichment pathway joint analysis of integrated DNA methylation and / or transcriptome and / or proteome data; automatic arrangement, verification, visualization and report generation of analysis results are realized; all operation steps can be traced, and corresponding analysis log records are generated. The invention further discloses a related system and application.

The invention discloses an integrated micro-fluidic chip which comprises a chip main body consisting of a reaction layer, a channel layer and a detection layer which are sequentially sealed from top to bottom in the vertical direction, the chip main body internally comprises a first fluid channel network and a second fluid channel network; the first fluid channel network comprises a first reaction chamber, a first mixing unit, a first transfer sample injection unit, a first digital detection unit and a fluid channel for connecting the structural units, which are communicated in sequence; the first fluid channel network and the second fluid channel network have the same structure and size, and the first fluid channel network and the second fluid channel network are arranged in a mirror symmetry mode along the central symmetry axis of the chip body. According to the chip disclosed by the invention, methylation sensitive incision enzyme digestion treatment, reagent mixing and digital amplification detection can be integrated on a closed micro-fluidic platform, and'sample input-result output 'is realized for the first time aiming at DNA methylation quantitative detection.

The invention relates to a tumor-related DNA methylation marker combination, which is selected from at least one of the following: a target sequence as shown in SEQ ID NO: 1-SEQ ID NO: 10, a nucleic acid fragment with the length of at least 15 oligonucleotides or a complementary nucleic acid fragment thereof, and the nucleic acid fragment comprises at least one methylation site indicated by CG. The invention also relates to a detection kit for the methylation marker combination. According to the invention, the combination of the co-methylation states of a plurality of specific methylation regions is used for distinguishing and analyzing the occurrence of tumors, especially kidney cancer, the specific methylation combination has high sensitivity for distinguishing the occurrence of kidney cancer, and the detection method is simple, convenient and feasible. The primer pair combination of the kit overcomes the defect of false positive caused by detection mismatch of a single methylation site in the aspect of primer sequence design, and the interaction between a plurality of methylation biomarker primers and probe pair combinations is considered.

The invention discloses heat-resistant saccharomyces cerevisiae of a heterozygous human DNA methylation system as well as a construction method and application of the heat-resistant saccharomyces cerevisiae. The construction method comprises the following steps: determining a to-be-knocked-in saccharomyces cerevisiae target gene locus CAN1, and carrying out annular PCR amplification by taking a target sgRNA sequence as a homologous arm and an original gRNA plasmid as a template to obtain a gRNA plasmid; constructing a to-be-knocked-in gene segment, and transferring the constructed gRNA plasmid, the segment 1 and the segment 2 into BY4741-Cas9 saccharomycetes through a saccharomyces cerevisiae lithium acetate conversion method; the CRISPR plasmid is lost by adopting an iteration method to obtain a saccharomyces cerevisiae strain which is integrated into a genome and has DNA methylation modification, and the saccharomyces cerevisiae strain is named as yHL006. The invention constructs a saccharomyces cerevisiae chassis strain capable of stably expressing a DNA methylation system. Any auxotrophic selection marker is not occupied, and the complete amino acid synthesis capability and corresponding gene loci of the yeast are completely reserved. The heat stress resistance phenotype of the DNA methylation strain is verified, and the heat resistance of the yeast can be improved by the introduced DNA methylation system.

The present invention relates to a method of evaluating the effect of at least one test component of an animal feed on at least the performance and / or the overall health of a test animal consuming an animal feed having the test component, the method comprising the steps of: (a) determining a test methylation profile of one or more preselected methylation sites within the DNA of the test animal; (b) comparing the test methylation profile from (a) to at least one control methylation profile from a control animal consuming animal feed free of the test component belonging to the same biologic classification unit as the test animal; and wherein the results of (a) are used to determine the performance and / or overall health of the test animal; and (c) comparing the test methylation profile from (a) to (i) a first reference methylation profile from a control animal having good performance and / or overall health belonging to the same biologic classification unit as the test animal; and / or (ii) a second reference methylation profile derived from a control animal having poor performance and / or overall health, belonging to the same bioclassification unit as the test animal; and wherein a significant similarity of the test methylation profile of (a) compared to the control methylation profile indicates that the test component has no effect on the performance and / or overall health of the test animal; and wherein a significant difference in the test methylation profile of (a) compared to the control methylation profile indicates that the test component has an effect on the performance and / or overall health of the test animal; and wherein a significant similarity of the test methylation profile of (a) to the first reference methylation profile and / or a difference of the test methylation profile of (a) to the second reference methylation profile indicates that the test animal has good performance and / or overall health as a control cell; and / or wherein the difference in the test methylation profile of (a) compared to the first reference methylation profile and / or the significant similarity of the test methylation profile of (a) to the second reference methylation profile indicates that the test animal has poor performance and / or overall health as a control animal; and wherein the test animal is selected from livestock or poultry.

The present invention belongs to the field of molecular biology and genetics, and in particular relates to a method for editing a bovine gene based on Pro-iCHI. The present invention provides a method for editing a bovine gene based on Pro-iCHI. Protamine is transiently expressed in gene-edited b-haSCs, which are then injected to mature oocytes to obtain reconstructed embryos. Protamine can eliminate abnormal DNA methylation resulting from oocyte intracytoplasmic haSCs injection and enable the nucli to compress into sperm-like structures, and the obtained bovine Pro-iCHI embryos can successfully develop into blastocysts, with a blastocyst rate comparable to that of the embryos obtained by in vitro fertilization. Moreover, in the present invention, a protamine-encoding gene is inserted into a Saccharomyces cerevisiae protein expression vector for transient expression, which ensures that abnormal DNA methylation is erased, without integration into the genome resulting in the insertion of exogenous genes.

The application discloses a kind of based on DNA methylation's construction method of biological age prediction model, the application is downloaded from GEO data website, derived from Chinese population, contains calendar age data, whole blood sample 450k methylation chip data, by the method of elastic network combined bootstrap, 31 methylation sites of modeling candidate are screened, multiple linear regression, support vector machine, random forest and gradient boosting regression tree are used to carry out preliminary construction and evaluation of model, then further filter methylation sites using full subset regression, obtain methylation age prediction model based on 18 methylation sites.Finally, using any provincial team natural population data, methylation age prediction model is optimized, and finally the biological age prediction model based on 18 methylation sites is obtained.The model is suitable for Chinese population, the number of methylation sites contained is less, is not affected by blood cell components, and the prediction accuracy is good.

The invention provides a marker for evaluating biological age, a probe composition and application thereof. The marker is an SCGN gene and / or a TRIM59 gene. According to the present invention, with the application of the marker, the methylation state of the genes can be sensitively and specifically detected, and the marker is used for constructing the age prediction model based on DNA methylation so as to detect the biological age.

The present disclosure includes, among other things, methods, kits, and systems for determining a status of lung cancer. In various embodiments, the present disclosure relates to the use of one or more histone modifications, chromatin accessibility, binding of one or more transcription factors, and / or DNA methylation as features of a status of lung cancer. In some embodiments, differential modifications and / or differential accessibility are detected and quantified at one or more genomic loci in a biological sample, e.g., cell-free DNA (cfDNA), from a liquid biopsy sample obtained or derived from a subject having lung cancer. In various embodiments, the determined status can be used, e.g., to select a treatment for lung cancer and / or to treat lung cancer.

The invention discloses a mental disease typing method and system integrating DNA methylation and neuroimaging, and the method is a neuroimaging biological annotation method integrating DNA methylation and brain connection group data, and comprises the steps: recognizing brain network features related to a specific molecular phenotype in a whole brain range through a machine learning model; and mechanism-sensitive layering of the mental disorder heterogeneity group is realized. The method does not need to depend on a prior classification or hypothesis mechanism, can be suitable for different types of mental disorder people, provides technical support for exploring potential biological mechanisms and identifying targeted therapy groups, and has high generalizability and clinical application prospects.

The invention provides oligonucleotide targeting DNMT1, a composition or a vector containing the oligonucleotide, a method for regulating DNMT1 expression by using the oligonucleotide, and a method for screening a target gene regulated by DNA methylation. The invention also provides a compound targeting the LIFR, a composition or a vector containing the compound and a method for regulating the expression of the LIFR by using the compound.

The present disclosure includes, among other things, methods, kits, and systems for determining the status of MS in a subject. In various embodiments, the present disclosure relates to the use of one or more histone modifications, chromatin accessibility, binding of one or more transcription factors, and / or DNA methylation that are characteristic of the status of MS. In some embodiments, differential modifications and / or differential accessibility are detected and quantified, at one or more genomic loci of a biological sample, e.g., in cell-free DNA (cfDNA) from a liquid biopsy sample obtained or derived from a subject with MS. In various embodiments a determined status is useful, e.g., in selecting treatment for and / or treating MS.

This invention relates to a method and system for screening osteoarthritis biomarkers based on Trans-CNN feature fusion, and relates to the field of medical technology. It addresses the problem that in existing osteoarthritis biomarker screening research, traditional Transformer models excel at capturing global relationships of features in input text sequences, while traditional CNN models focus more on local feature relationships. The fusion of these two approaches can reduce the accuracy of osteoarthritis diagnosis. The proposed Trans-CNN feature fusion model cleverly combines the global context awareness capability of Transformer with the local feature extraction advantage of CNN through a dynamic gating mechanism. This enables a more comprehensive capture of the complex regulatory relationships in DNA methylation data, thus facilitating the screening of osteoarthritis biomarkers.

The present invention relates to DNA methylation markers for diagnosing esophageal cancer and gastric cancer and uses thereof, more particularly to a combination of DNA methylation markers capable of determining the presence or absence of esophageal cancer and gastric cancer and uses thereof. The DNA methylation markers for diagnosing esophageal cancer and gastric cancer according to the present invention can diagnose esophageal cancer and gastric cancer with high accuracy using only DNA methylation information from blood samples without using esophageal cancer and gastric cancer tissue samples, and can therefore be useful for the early diagnosis of esophageal cancer and gastric cancer.

The invention provides a multi-omics integrated marker for early screening of colorectal cancer, which comprises an lncRNA marker combination, a protein marker combination, an mRNA marker combination, a metabolism marker combination and a methylation marker combination, and relates to the technical field of gene detection and medical treatment. According to the invention, 11 groups of colorectal cancer tissues and para-carcinoma tissues paired with the colorectal cancer tissues are subjected to transcriptome, proteome and metabolome sequencing, and 61 cases of colorectal cancer tissues and 24 cases of para-carcinoma tissues are subjected to simplified methylation sequencing; by integrating and analyzing the multi-omics data, a multi-level interaction network is obtained, and the network contains lncRNA, protein, mRNA, metabolites and DNA methylation markers which have a close interaction relationship, and has a wide application prospect in diagnosis and treatment of colorectal cancer.

Plants, plant parts, and a population of plants or plant parts comprising reduced BIG SEEDS (BS) activity, and compositions and methods of producing such plants, plant parts, and a population of plants and plant parts are provided. The plants, plant parts, or population can have a genetic mutation or a modification of the DNA methylation pattern that reduces the BIG SEEDS activity, which can be located at least partially in at least one BS gene or homolog or in its regulatory region. The plants, plant parts, and population can have increased organ size and / or protein or amino acid content. Also provided are seed, protein, and / or oil compositions and food and beverage products produced from the plants or plant parts provided herein.

The invention provides a DNA quantitative detection method based on a real methylation level and application of the DNA quantitative detection method in preparation of a bladder cancer detection kit. The method comprises the following steps: (1) DNA purification: purifying a DNA sample by adopting a sodium acetate method; (2) DNA oxidation: oxidizing the DNA purified in the step (1) by using a potassium perruthenate solution and a neutralizing oxidant; (3) DNA transformation: transforming the DNA oxidized in the step (2) by using a methylation detection sample pretreatment kit; and (4) qRT-PCR detection of the DNA: detecting the DNA converted in the step (3) by using a DNA methylation qRT-PCR mixed system to complete quantitative detection of the DNA. The method provided by the invention is simple and convenient to operate and high in specificity, can effectively remove interference of hydroxymethylation and truly reflect DNA methylation filling, and is suitable for early diagnosis, recurrence prediction and the like of bladder cancer.

This invention discloses the application of substances that increase LSH content or activity in improving heterochromatin stability and enhancing the efficacy of cell therapy, belonging to the field of biomedical technology. This invention, through overexpression of LSH in IMR90 fibroblasts and T lymphocytes, successfully achieved for the first time complete inhibition of DNA methylation loss in heterochromatin regions during cell expansion. The innovative research results of this invention strongly demonstrate that the insufficient DNA methylation maintenance efficiency caused by the dense chromatin environment in heterochromatin regions is the reason for the continuous loss of DNA methylation during sustained cell expansion. Overexpression of LSH can effectively improve the DNA methylation maintenance efficiency in heterochromatin regions to prevent DNA methylation loss, thereby improving several phenotypic defects caused by sustained cell expansion. This provides a new strategy for effectively maintaining cell function in adoptive cell therapy and has broad application value in enhancing the efficacy of various cell therapies.

A system for early warning of coronary heart disease. A computer device comprises a memory, a processor, and a computer program stored on the memory. The processor executes the computer program to implement the following steps: receiving methylation level data of a DNA methylation marker combination of a potential coronary heart disease patient and a healthy control sample, establishing a mathematical model, and determining a threshold; and inputting methylation level data of the DNA methylation marker combination of a subject to be tested and substituting same into the mathematical model to obtain a detection index, and comparing the detection index with the threshold to obtain a conclusion of whether a sample to be tested belongs to the potential coronary heart disease patient or the healthy control. The present invention has important scientific significance and clinical application value in early warning of coronary heart disease and diagnosis and treatment of coronary heart disease.

The present invention relates to a composition, a kit, and a method, for detecting the methylation level of CpG regions of genes to diagnose Alzheimer's disease dementia, diagnose mild cognitive impairment of Alzheimer's disease, diagnose Alzheimer's disease dementia early, or predict the risk of progression to Alzheimer's disease dementia.

The present application relates to the field of second-generation sequencing, in particular to the field of methylation sequencing, and more particularly to a marker sequence, a linker comprising the marker sequence, a kit comprising the sequence or the linker, and a DNA methylation sequencing method using the linker or the kit. The marker sequence comprises a polycytosine sequence on one side or both sides of an insert, wherein each cytosine at each site on each side has two states of modification or no modification. The present application can reduce cross-contamination between sequencing samples, and can be applied to DNA methylation detection.

In one aspect, the disclosure relates to methods for monitoring clonal hematopoiesis of indeterminate potential (CHIP) in a subject, the method including at least performing DNA methylation sequencing on DNA from the subject, performing cell-type deconvolution from the methylation data to estimate a first set of cell-type proportions in the subject, repeating the method to determine a second set of cell-type proportions in the subject, and monitoring a change in variant allele fraction (VAF) using methylation data collected during performance of the method in conjunction with the first set of cell-type proportions and the second set of cell-type proportions. Also disclosed are methods for assessing the performance of a drug for treating a blood cancer.

The invention provides a product and a method for detecting urinary tract epithelial carcinoma based on DNA methylation, and belongs to the technical field of urinary tract epithelial carcinoma detection, the product comprises reagents for detecting methylation of the following DNA regions: a PENK gene CpG island region Chr8: 56446618-56446724, a TMEM106A gene CpG island region Chr17: 43211685-43211847, and an OTX1 gene CpG island region Chr2: 63056808-63056956. Through joint detection of the target gene areas, accurate prediction of urothelial carcinoma is realized, and the kit has comprehensive coverage (bladder cancer, pelvis cancer and ureteral cancer) and detection advantages of early and low-grade cancers, can be used for early screening, postoperative recurrence monitoring, prognosis evaluation and other stages, and has a wide application prospect in the fields of early screening, postoperative recurrence monitoring, prognosis evaluation and the like. The positive significance is realized on the whole disease course management of the urothelial carcinoma.

The invention relates to a multi-dimensional anti-aging composition suitable for sensitive skin and application, and belongs to the technical field of cosmetics. The multi-dimensional anti-aging composition suitable for sensitive skin is prepared from a Burbury leaf extract, a rice extract, an ulmus pumila bark extract and an anise leaf extract, and the four components are reasonably compounded. The synergistic anti-aging effect is achieved from a plurality of levels of regulating DNA methylation from a gene level, relieving endoplasmic reticulum stress from a cell level, maintaining collagen synthesis and degradation balance from a metabolism level, strengthening a skin barrier and the like.

Methods for monitoring circannual rhythms and / or determining birth period by detecting DNA methylation and oligonucleotide arrays therefor.

The application provides a DNA methylation-based gene point site screening method, which comprises the following steps: 1) obtaining initial parameters of a gene point site screening model through meta-learning; and 2) retraining the gene point site screening model based on the initial parameters obtained in step 1). The method provided by the application can alleviate the overfitting phenomenon during training of the gene point site screening model.